Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
18.48
-0.09 (-0.48%)
At close: Oct 30, 2026, 4:00 PM EDT
19.89
+1.41 (7.63%)
After-hours: Oct 30, 2026, 7:56 PM EDT
Nuvectis Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q4 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Selling, General & Admin | 9.22 | 9.69 | 9.42 | 8.84 | 8.36 | 7.08 | 6.93 | 7.58 | 7.71 | 7.52 | 7.52 | 7.3 | 7.04 | 6.6 | 6.01 | 4.75 | 3.84 | 4.47 | 3.35 | 0.02 |
Research & Development | 19.65 | 18.58 | 18.15 | 17.56 | 14.61 | 13.94 | 12.92 | 11.69 | 13.35 | 14.67 | 14.38 | 14.31 | 14.35 | 12.59 | 12.03 | 2.87 | 2.51 | 4.25 | 2.45 | - |
Operating Expenses | 28.87 | 28.27 | 27.57 | 26.41 | 22.97 | 21.02 | 19.85 | 19.26 | 21.06 | 22.19 | 21.9 | 21.61 | 21.39 | 19.19 | 18.03 | 7.62 | 6.35 | 8.72 | 5.79 | 0.02 |
Operating Income | -28.87 | -28.27 | -27.57 | -26.41 | -22.97 | -21.02 | -19.85 | -19.26 | -21.06 | -22.19 | -21.9 | -21.61 | -21.39 | -19.19 | -18.03 | -7.62 | -6.35 | -8.72 | -5.79 | -0.02 |
Interest & Investment Income | 1.02 | 1.11 | 1.13 | 1.03 | 0.9 | 0.86 | 0.85 | 0.89 | 0.96 | 0.81 | 0.64 | 0.48 | 0.26 | 0.2 | 0.15 | 0.07 | 0.01 | 0.01 | 0 | - |
EBT Excluding Unusual Items | -27.85 | -27.16 | -26.44 | -25.38 | -22.07 | -20.16 | -19 | -18.37 | -20.1 | -21.38 | -21.26 | -21.13 | -21.13 | -18.99 | -17.89 | -7.55 | -6.34 | -8.71 | -5.79 | -0.02 |
Other Unusual Items | - | - | - | - | - | - | - | -1 | -1 | -1 | -1 | -1.2 | -1.2 | -1.2 | -1.2 | -7.1 | -7.1 | -7.1 | -7.1 | - |
Pretax Income | -27.85 | -27.16 | -26.44 | -25.38 | -22.07 | -20.16 | -19 | -19.37 | -21.1 | -22.38 | -22.26 | -22.33 | -22.33 | -20.19 | -19.09 | -14.65 | -13.44 | -15.81 | -12.89 | -0.02 |
Net Income | -27.85 | -27.16 | -26.44 | -25.38 | -22.07 | -20.16 | -19 | -19.37 | -21.1 | -22.38 | -22.26 | -22.33 | -22.33 | -20.19 | -19.09 | -14.65 | -13.44 | -15.81 | -12.89 | -0.02 |
Preferred Dividends & Other Adjustments | 2.43 | 2.43 | 2.43 | 2.43 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income to Common | -30.28 | -29.59 | -28.87 | -27.81 | -22.07 | -20.16 | -19 | -19.37 | -21.1 | -22.38 | -22.26 | -22.33 | -22.33 | -20.19 | -19.09 | -14.65 | -13.44 | -15.81 | -12.89 | -0.02 |
Net Income Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shares Outstanding (Basic) | 23 | 23 | 22 | 20 | 19 | 18 | 17 | 17 | 16 | 16 | 16 | 15 | 15 | 14 | 13 | 10 | 8 | 6 | 4 | 4 |
Shares Outstanding (Diluted) | 23 | 23 | 22 | 20 | 19 | 18 | 17 | 17 | 16 | 16 | 16 | 15 | 15 | 14 | 13 | 10 | 8 | 6 | 4 | 4 |
Shares Change (YoY) | 21.66% | 26.31% | 27.46% | 22.30% | 16.00% | 12.13% | 10.01% | 10.23% | 12.32% | 14.00% | 22.90% | 49.95% | 89.00% | 151.63% | 196.55% | - | - | - | 9.44% | - |
EPS (Basic) | -1.30 | -1.30 | -1.32 | -1.36 | -1.16 | -1.12 | -1.11 | -1.16 | -1.28 | -1.40 | -1.43 | -1.47 | -1.53 | -1.44 | -1.51 | -1.45 | -1.74 | -2.83 | -3.02 | - |
EPS (Diluted) | -1.30 | -1.30 | -1.32 | -1.36 | -1.16 | -1.12 | -1.11 | -1.16 | -1.28 | -1.40 | -1.43 | -1.47 | -1.53 | -1.44 | -1.51 | -1.45 | -1.74 | -2.83 | -3.02 | - |
EPS Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Additional Metrics
Fiscal Quarter | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q4 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
EBIT | -28.87 | -28.27 | -27.57 | -26.41 | -22.97 | -21.02 | -19.85 | -19.26 | -21.06 | -22.19 | -21.9 | -21.61 | -21.39 | -19.19 | -18.03 | -7.62 | -6.35 | -8.72 | -5.79 | -0.02 |